Dr. Reddy’s Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market


Hyderabad, June 9: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax® (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).  

The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health*.

Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.

Angiomax® is a registered trademark of The Medicines Company. 

*IMS National Sales Perspective: Retail and Non-Retail MAT March 2017


About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.